Phase I Trial of Neoadjuvant Preoperative Chemotherapy With S-1 and Irinotecan Plus Radiation in Patients With Locally Advanced Rectal Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 5, 2007, Pages 1442-1447

  Sato, Takeo ^a   Kokuba, Yukihito ^a   Koizumi, Wasaburo ^a   Hayakawa, Kazushige ^a   Okayasu, Isao ^a   Watanabe, Masahiko ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Irinotecan; Neoadjuvant chemoradiotherapy; Rectal cancer; S 1

Indexed keywords

CHEMOTHERAPY; DISEASE CONTROL; DRUG DOSAGE; ONCOLOGY;

IRINOTECAN; NEOADJUVANT CHEMORADIOTHERAPY; RECTAL CANCER;

RADIOTHERAPY;

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECTUM CANCER; SPHINCTER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OXONIC ACID; RECTAL NEOPLASMS; TEGAFUR;

EID: 36148944449     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.081     Document Type: Article

References (21)

1. Weitz J., Koch M., Debus J., et al. Colorectal cancer. Lancet 365 (2005) 153-165
2. Marugame T., Kamo K., Katanoda K., et al. Cancer incidence and incidence rates in Japan in 2000: Estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol 36 (2006) 668-675
3. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
4. Yamada Y., Hamaguchi T., Goto M., et al. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 89 (2003) 816-820
5. Ohtsu A., Baba H., Sakata Y., et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83 (2000) 141-145
6. Shirao K., Ohtsu A., Takada H., et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100 (2004) 2355-2361
7. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355 (2000) 1041-1047
8. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (2000) 905-914
9. Mehta V.K., Cho C., Ford J.M., et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55 (2003) 132-137
10. Mitchell E.P., Winter K., Mohiuddin M., et al. Randomized phase II trial of preoperative combined modality chemoradiation for distal rectal cancer (Abstr. 3535). J Clin Oncol 22 (2004) 254
11. Hofheinz R.D., von Gerstenberg-Helldorf B., Wenz F., et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23 (2005) 1350-1357
12. Klautke G., Feyerherd P., Ludwig K., et al. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer 92 (2005) 1215-1220
13. Japanese Society for Cancer of the Colon and Rectum. General rules for clinical and pathological studies on cancer of the colon, rectum, and anus. 6th ed. (1998), Kanehara & Co., Tokyo
14. Sauer R., Roedel C., Martus P., et al. Prognostic factors after neoadjuvant radiochemotherapy for rectal cancer: Update of the CAO/ARO/AIO-94 phase III study (Abstr. 3503). J Clin Oncol 23 (2005) 246s
15. Que B.G., Ardalan B., and Richman S. Camptosar reduced the thymidylate synthase gene expression in 5-FU-resistant cell line (Abstr. 4763). Proc Am Assoc Cancer Res 41 (2000) 749
16. Guichard S., Hennebelle I., Bugat R., et al. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55 (1998) 667-676
17. Ichikawa W., Uetake H., Nihei Z., et al. Topoisomerase I expression correlates to thymidylate synthase expression in colorectal cancer (Abstr. 946). Proc Am Soc Clin Oncol 17 (1999) 946
18. Ichikawa W., Takahashi T., Suto K., et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91 (2004) 1245-1250
19. Takechi T., Nakano K., Uchida J., et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39 (1997) 205-211
20. Fukushima M., Ohshimo H., and Taguchi T. Combined therapy with radiation and S-1, an oral new 5-FU prodrug, is markedly effective against non-small cell lung cancer xenografts in mice. Eur J Cancer 3 (2005) 343
21. Borner M.M., Schoffski P., de Wit R., et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38 (2002) 349-358